Researchers developed a probiotic-inspired drug delivery system targeting the gut–brain axis. In Parkinson’s mouse models, it ...
I would like to start a regular segment where I explain the latest findings for therapists!For our momentous first ...
Biochemical and animal studies suggest that cocoa-derived theobromine can affect monoamine oxidase, adenosine and neuronal ...
A 30-year innovation has arrived in Parkinson's disease treatment. The US FDA has approved AbbVie's new drug, 'Juvmo.' The ...
A multimodal imaging and voice-analysis study of early Parkinson's disease reveals that speech impairment arises from dopaminergic loss and striatal connectivity disruption in men but primarily ...
The novel GPR6 inhibitor met its primary endpoint in the phase 3 ARISE trial, achieving a statistically significant reduction in daily OFF time and demonstrating non-dopaminergic motor and ...
Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2Statistically significant improvements in secondary endpoints of ON time without ...
Newswise — A new clinical trial led by Yale School of Medicine's Jesse Cedarbaum, MD, professor of neurology, and David Hafler, MD, William S. and Lois Stiles Edgerly Professor of Neurology, is the ...
It’s true. Rates of Parkinson’s disease are growing faster than any other neurological condition in the world, with incidence projected to double in the coming decades. Parkinson’s is a progressive ...
When Parkinson's disease destroys a person's capacity for movement, it is not the muscles that fail — it is the brain's clock. The official trailer for Onwards and Sideways, released September 2 ahead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results